Two faces of drug therapy in cancer: drug-related lean tissue loss and its adverse consequences to survival and toxicity

Purpose of reviewA common feature of cancer patients is loss of lean tissue, specifically skeletal muscle, which may be the result of the tumor or a side-effect of chemotherapy or other drugs. Lean tissue loss in turn has important adverse implications for toxicity of antineoplastic therapy and, hence, cancer prognosis. Recent findingsContemporary cancer populations have heterogeneous proportions of lean tissue, regardless of body weight. Wasting of lean tissue during the cancer trajectory has been associated with tumor progression. Lean tissue depletion is an independent predictor of severe toxicity in patients treated with chemotherapeutic agents of diverse classes. Patients with lean tissue depletion behave as if overdosed and have toxicity of sufficient magnitude to require dose reductions, treatment delays or definitive termination of treatment. Muscle loss may occur due to a specific effect of a chemotherapy agent (i.e. sorafenib), androgen suppression therapy or other drugs (i.e. statins such as atorvastatin). SummaryLean tissue wasting occurs due to cancer progression and may be exacerbated by several drug classes. This loss of lean tissue is not proportional to changes in body weight and is prognostic of enhanced treatment toxicity and reduced survival.

[1]  Yiannis S. Chatzizisis,et al.  Risk Factors and Drug Interactions Predisposing to Statin-Induced Myopathy Implications for Risk Assessment , Prevention and Treatment , 2012 .

[2]  D. Cella,et al.  Muscle wasting in cancer cachexia: clinical implications, diagnosis, and emerging treatment strategies. , 2011, Annual review of medicine.

[3]  K. Huey,et al.  Statin‐associated myopathy and its exacerbation with exercise , 2010, Muscle & nerve.

[4]  L. Birdsell,et al.  Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[5]  R. Weichselbaum,et al.  Statin use and risk of prostate cancer recurrence in men treated with radiation therapy. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Tony Reiman,et al.  Body composition in patients with non-small cell lung cancer: a contemporary view of cancer cachexia with the use of computed tomography image analysis. , 2010, The American journal of clinical nutrition.

[7]  L. Birdsell,et al.  Association of skeletal muscle wasting with treatment with sorafenib in patients with advanced renal cell carcinoma: results from a placebo-controlled study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  P. Saylor,et al.  Adverse effects of androgen deprivation therapy: defining the problem and promoting health among men with prostate cancer. , 2010, Journal of the National Comprehensive Cancer Network : JNCCN.

[9]  D. Khemasuwan,et al.  Statins decrease the occurrence of venous thromboembolism in patients with cancer. , 2010, The American journal of medicine.

[10]  L. Mccargar,et al.  An exploratory study of body composition as a determinant of epirubicin pharmacokinetics and toxicity , 2010, Cancer Chemotherapy and Pharmacology.

[11]  L. Birdsell,et al.  The emerging role of computerized tomography in assessing cancer cachexia , 2009, Current opinion in supportive and palliative care.

[12]  Lisa Martin,et al.  Sarcopenia in an Overweight or Obese Patient Is an Adverse Prognostic Factor in Pancreatic Cancer , 2009, Clinical Cancer Research.

[13]  J. Thissen,et al.  Mechanisms of Muscle Atrophy Induced by Glucocorticoids , 2009, Hormone Research in Paediatrics.

[14]  R. Newton,et al.  Reduced muscle strength and functional performance in men with prostate cancer undergoing androgen suppression: a comprehensive cross-sectional investigation , 2009, Prostate Cancer and Prostatic Diseases.

[15]  P. Saylor,et al.  Metabolic complications of androgen deprivation therapy for prostate cancer. , 2009, The Journal of urology.

[16]  L. Mccargar,et al.  Sarcopenia as a Determinant of Chemotherapy Toxicity and Time to Tumor Progression in Metastatic Breast Cancer Patients Receiving Capecitabine Treatment , 2009, Clinical Cancer Research.

[17]  Kevin D Hall,et al.  A viscerally driven cachexia syndrome in patients with advanced colorectal cancer: contributions of organ and tumor mass to whole-body energy demands. , 2009, The American journal of clinical nutrition.

[18]  Tony Reiman,et al.  A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine care. , 2008, Applied physiology, nutrition, and metabolism = Physiologie appliquee, nutrition et metabolisme.

[19]  Tony Reiman,et al.  Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. , 2008, The Lancet. Oncology.

[20]  J. Thissen,et al.  Mechanisms of glucocorticoid-induced myopathy. , 2008, The Journal of endocrinology.

[21]  Tony Reiman,et al.  Body Composition as an Independent Determinant of 5-Fluorouracil–Based Chemotherapy Toxicity , 2007, Clinical Cancer Research.

[22]  C. Thompson,et al.  Akt maintains cell size and survival by increasing mTOR-dependent nutrient uptake. , 2002, Molecular biology of the cell.

[23]  D. Lindquist,et al.  Effects of testosterone replacement and/or resistance exercise on the composition of megestrol acetate stimulated weight gain in elderly men: a randomized controlled trial. , 2002, The Journal of clinical endocrinology and metabolism.

[24]  G. Yancopoulos,et al.  Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy in vivo , 2001, Nature Cell Biology.

[25]  S. Goodinson.  Assessment of nutritional status. , 1987, Professional nurse.

[26]  H. Hewitt.  Nutrition and the cancer patient. , 1978, British medical journal.